Tenders Are Invited For Immune Sera And Immunoglobulins – Medicine With The Active Substance Palivizumab in Slovakia

Work Detail

Immune Sera And Immunoglobulins – Medicine With The Active Substance Palivizumab. The Subject Of The Contract Is: Medicine With The Active Substance Palivizumab Palivizumab Is A Recombinant Humanized Monoclonal Antibody Produced By Dna Technology In Mouse Myeloma Host Cells. One 0.5 Ml Vial Contains 50 Mg Of Palivizumab The Drug Is Indicated For The Prevention Of Severe Lower Respiratory Tract Disease Requiring Hospitalization Caused By Respiratory Syncytial Virus (Rsv) In Children At High Risk Of Rsv Disease: • Children Who Were Born At 35 Weeks Of Pregnancy Or Earlier And Are Younger Than 6 Months At The Beginning Of The Rsv Season; • Children Under 2 Years Of Age Who Have Needed Treatment For Bronchopulmonary Dysplasia In The Last 6 Months; • Children Under 2 Years Of Age With Hemodynamically Significant Congenital Heart Disease

Contact Information